MYH9-TXN2 Fusion FISH Probe
The MYH9-TXN2 Fusion FISH Probe is used to confirm a fusion of the MYH9 and TXN2 genes. The fusion of the MYH9 and TXN2 genes has been associated with Ovarian Serous Cystadenocarcinoma, Lung Adenocarcinoma, Liver Hepatocellular Carcinoma, Head And Neck Squamous Cell Carcinoma , and Uterine Corpus Endometrial Carcinoma. These probes are FISH confirmed on normal peripheral blood in both interphase nuclei and metaphase spreads before shipment. Typical turnaround time for this product is 7-14 days after purchase.
** This product is for in vitro and research use only. This product is not intended for diagnostic use. Please note that both genes fall on the same chromosome and inter-chromosomal detection may be difficult to detect depending on the genes proximity to one another. Please consult our support staff before ordering this product to ensure that the probe can be designed to meet your specific needs.
| SKU | Test Kits | Buffer | Dye Color | Order Now |
|---|---|---|---|---|
| MYH9-TXN2-20-ORGR (Standard Design) | 20 (40 μL) | 200 μL |
|
|
| MYH9-TXN2-20-RERE | 20 (40 μL) | 200 μL |
|
|
| MYH9-TXN2-20-REOR | 20 (40 μL) | 200 μL |
|
|
| MYH9-TXN2-20-REGO | 20 (40 μL) | 200 μL |
|
|
| MYH9-TXN2-20-REGR | 20 (40 μL) | 200 μL |
|
|
| MYH9-TXN2-20-REAQ | 20 (40 μL) | 200 μL |
|
|
| MYH9-TXN2-20-ORRE | 20 (40 μL) | 200 μL |
|
|
| MYH9-TXN2-20-OROR | 20 (40 μL) | 200 μL |
|
|
| MYH9-TXN2-20-ORGO | 20 (40 μL) | 200 μL |
|
|
| MYH9-TXN2-20-ORAQ | 20 (40 μL) | 200 μL |
|
|
| MYH9-TXN2-20-GORE | 20 (40 μL) | 200 μL |
|
|
| MYH9-TXN2-20-GOOR | 20 (40 μL) | 200 μL |
|
|
| MYH9-TXN2-20-GOGO | 20 (40 μL) | 200 μL |
|
|
| MYH9-TXN2-20-GOGR | 20 (40 μL) | 200 μL |
|
|
| MYH9-TXN2-20-GOAQ | 20 (40 μL) | 200 μL |
|
|
| MYH9-TXN2-20-GRRE | 20 (40 μL) | 200 μL |
|
|
| MYH9-TXN2-20-GROR | 20 (40 μL) | 200 μL |
|
|
| MYH9-TXN2-20-GRGO | 20 (40 μL) | 200 μL |
|
|
| MYH9-TXN2-20-GRGR | 20 (40 μL) | 200 μL |
|
|
| MYH9-TXN2-20-GRAQ | 20 (40 μL) | 200 μL |
|
|
| MYH9-TXN2-20-AQRE | 20 (40 μL) | 200 μL |
|
|
| MYH9-TXN2-20-AQOR | 20 (40 μL) | 200 μL |
|
|
| MYH9-TXN2-20-AQGO | 20 (40 μL) | 200 μL |
|
|
| MYH9-TXN2-20-AQGR | 20 (40 μL) | 200 μL |
|
|
| MYH9-TXN2-20-AQAQ | 20 (40 μL) | 200 μL |
|
MYH9 Gene Summary
This gene encodes a conventional non-muscle myosin; this protein should not be confused with the unconventional myosin-9a or 9b (MYO9A or MYO9B). The encoded protein is a myosin IIA heavy chain that contains an IQ domain and a myosin head-like domain which is involved in several important functions, including cytokinesis, cell motility and maintenance of cell shape. Defects in this gene have been associated with non-syndromic sensorineural deafness autosomal dominant type 17, Epstein syndrome, Alport syndrome with macrothrombocytopenia, Sebastian syndrome, Fechtner syndrome and macrothrombocytopenia with progressive sensorineural deafness. [provided by RefSeq, Dec 2011]
Gene Name: Myosin Heavy Chain 9
Chromosome: CHR22: 36677322 -36784063
Locus: 22q12.3
TXN2 Gene Summary
This nuclear gene encodes a mitochondrial member of the thioredoxin family, a group of small multifunctional redox-active proteins. The encoded protein may play important roles in the regulation of the mitochondrial membrane potential and in protection against oxidant-induced apoptosis. [provided by RefSeq, Jul 2008]
Gene Name: Thioredoxin 2
Chromosome: CHR22: 36863092 -36877687
Locus: 22q12.3
Gene Diseases
The MYH9 TXN2 Fusion has been associated with the following diseases:
| Disease Name |
|---|
| Ovarian Serous Cystadenocarcinoma |
| Lung Adenocarcinoma |
| Liver Hepatocellular Carcinoma |
| Head And Neck Squamous Cell Carcinoma |
| Uterine Corpus Endometrial Carcinoma |
FISH Probe Protocols
| Protocol, Procedure, or Form Name | Last Modified | Download |
|---|